Comparative Pharmacology
Head-to-head clinical analysis: AMTURNIDE versus HYDRA ZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMTURNIDE versus HYDRA ZIDE.
AMTURNIDE vs HYDRA-ZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
Hydra-Zide is a combination of hydrochlorothiazide (thiazide diuretic) and hydralazine (direct vasodilator). Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing electrolyte reabsorption and increasing urine output. Hydralazine relaxes arteriolar smooth muscle, decreasing systemic vascular resistance and afterload.
10 mg to 20 mg orally once daily, with or without food.
Oral, 1 tablet (25 mg hydrochlorothiazide / 50 mg hydralazine) twice daily, titrated up to maximum of 2 tablets twice daily based on blood pressure response.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); thiazide: 6-15 hours.
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
Renal: 50-70% of hydralazine as metabolites, 30-40% as parent drug; thiazide: 95% renal as unchanged drug.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination